4-(3-Bromo-pyridin-2-yl)-piperazine-1-carboxylic acid (4-isopropyl-phenyl)-amide | 579503-65-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(3-Bromo-pyridin-2-yl)-piperazine-1-carboxylic acid (4-isopropyl-phenyl)-amide
• 英文别名: 4-(3-Bromo-2-pyridinyl)-N-[4-(1-methylethyl)phenyl]-1-piperazinecarboxamide；4-(3-bromopyridin-2-yl)-N-(4-propan-2-ylphenyl)piperazine-1-carboxamide
• CAS: 579503-65-4
• 化学式: C₁₉H₂₃BrN₄O
• 分子量: 403.322
• InChiKey: FNALNVCQQLOHRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  48.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-溴-2-氯吡啶 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 8.0h， 生成 4-(3-Bromo-pyridin-2-yl)-piperazine-1-carboxylic acid (4-isopropyl-phenyl)-amide
  参考文献：
  名称：

  4-(2-Pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists

  摘要：

  A series of 4-(2-pyridyl)piperazine-1-carboxamide analogues based on the lead compound 1 was synthesized and evaluated for VR1 antagonist activity in capsaicin-induced (CAP) and pH (5.5)-induced (pH) FLIPR assays in a rat VR1-expressing HEK293 cell line. Potent VR1 antagonists were identified through SAR studies. From these studies, 18 was found to be very potent in the in vitro assay [IC50 = 4.8 nM (pH) and 35 nM (CAP)] and orally available in rat (F% = 15.1). (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00759-5

文献信息

• US7256193B2
  申请人：——

  公开号：US7256193B2

  公开（公告）日：2007-08-14
• 4-(2-Pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists
  作者：Qun Sun、Laykea Tafesse、Khondaker Islam、Xiaoming Zhou、Sam F. Victory、Chongwu Zhang、Mohamed Hachicha、Lori A. Schmid、Aniket Patel、Yakov Rotshteyn、Kenneth J. Valenzano、Donald J. Kyle

  DOI：10.1016/s0960-894x(03)00759-5

  日期：2003.10

  A series of 4-(2-pyridyl)piperazine-1-carboxamide analogues based on the lead compound 1 was synthesized and evaluated for VR1 antagonist activity in capsaicin-induced (CAP) and pH (5.5)-induced (pH) FLIPR assays in a rat VR1-expressing HEK293 cell line. Potent VR1 antagonists were identified through SAR studies. From these studies, 18 was found to be very potent in the in vitro assay [IC50 = 4.8 nM (pH) and 35 nM (CAP)] and orally available in rat (F% = 15.1). (C) 2003 Elsevier Ltd. All rights reserved.